First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [ 68 Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma
Journal of Nuclear Medicine · 2024-05 · 65 (5) · 740-743
DOI: 10.2967/jnumed.123.267175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 22.02.2024. Verfasst von Michael S Hofman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; michael.hofman@petermac.org. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
[68Ga]Ga-DPI-4452, a first-in-class carbonic anhydrase IX-binding radiolabeled peptide, is the imaging agent of a theranostic pair with [177Lu]Lu-DPI-4452, developed for selecting and treating patients with carbonic anhydrase IX-expressing tumors. Here, [68Ga]Ga-DPI-4452 imaging characteristics, dosimetry, pharmacokinetics, and safety were assessed in 3 patients with clear cell renal cell carcinoma.
Methods
After [68Ga]Ga-DPI-4452 administration, patients underwent serial full-body PET/CT imaging. Blood and urine were sampled. Safety was monitored for 7 d after injection.
Results
Tumor uptake was observed at all time points (15 min to 4 h). Across 36 lesions, the SUVmax at 1 h after administration ranged from 6.8 to 211.6 (mean, 64.6 [SD, 54.8]). The kidneys, liver, and bone marrow demonstrated low activity. [68Ga]Ga-DPI-4452 was rapidly eliminated from blood and urine. No clinically significant toxicity was observed. Conclusion: [68Ga]Ga-DPI-4452 showed exceptional tumor uptake in patients with clear cell renal cell carcinoma, with very high tumor-to-background ratios and no significant adverse events, suggesting potential diagnostic and patient selection applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; michael.hofman@petermac.org.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
- Debiopharm International SA, Lausanne, Switzerland; and.
- CDE Dosimetry Services, Inc., Knoxville, Tennessee.
Förderung
- NCI NIH HHS
Zitieren
APA
Hofman, M. S., Tran, B., Feldman, D. R., Pokorska-Bocci, A., Pichereau, S., Wessen, J., Haskali, M. B., Sparks, R. B., Vlasyuk, O., & Galetic, I. (2024). First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [ 68 Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma. Journal of Nuclear Medicine, 65(5), 740-743. https://doi.org/10.2967/jnumed.123.267175
Vancouver
Hofman MS, Tran B, Feldman DR, Pokorska-Bocci A, Pichereau S, Wessen J, et al. First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [ 68 Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma. Journal of Nuclear Medicine. 2024;65(5):740-743. doi:10.2967/jnumed.123.267175
BibTeX
@article{Hofman2024,
author = {Hofman, Michael S and Tran, Ben and Feldman, Darren R and Pokorska-Bocci, Anna and Pichereau, Solen and Wessen, Jonathan and Haskali, Mohammad B and Sparks, Richard B and Vlasyuk, Olena and Galetic, Ivana},
title = {First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [ 68 Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {5},
pages = {740--743},
doi = {10.2967/jnumed.123.267175}
}
EUVIMED